Integra LifeSciences (IART) – Major News
-
Integra LifeSciences (IART) Misses Q4 EPS by 1c, provides guidance
-
Integra LifeSciences (IART) Misses Q3 EPS by 2c; offers guidance
-
Integra LifeSciences (IART) Tops Q2 EPS by 14c
-
Integra LifeSciences (IART) Reports In-Line Q1 EPS; revenue beat; offers guidance
-
Integra LifeSciences (IART) Tops Q4 EPS by 4c; Offers FY23 Guidance
-
Integra LifeSciences (IART) Tops Q3 EPS by 12c
-
Integra LifeSciences (IART) Tops Q3 EPS by 12c; Offers Guidance
-
Integra LifeSciences (IART) Tops Q2 EPS by 2c; Offers FY22 Guidance
-
Integra LifeSciences (IART) Tops Q1 EPS by 6c
-
Integra LifeSciences (IART) Tops Q4 EPS by 1c; Offers 2022 Guidance
-
Integra LifeSciences (IART) Tops Q3 EPS by 14c
-
Integra LifeSciences (IART) Tops Q2 EPS by 13c
-
Integra LifeSciences (IART) Tops Q1 EPS by 12c, Updates Guidance
-
Integra LifeSciences (IART) Tops Q1 EPS by 12c, Updates Guidance
-
Integra LifeSciences (IART) Tops Q4 EPS by 11c; Offers 1Q EPS/Revenue Guidance Below Consensus, FY21 Revenues Views Below Consensus
-
Integra LifeSciences (IART) Tops Q3 EPS by 27c
-
Integra LifeSciences (IART) Tops Q2 EPS by 23c
-
Integra LifeSciences (IART) Misses Q1 EPS by 16c
-
Integra LifeSciences (IART) Tops Q4 EPS by 1c, Revenues Miss; Offers FY20 EPS Mid-Point Guidance Above Consensus, FY20 Revenue Outlook Below Consensus
-
Integra LifeSciences (IART) Tops Q3 EPS by 3c, Updates FY Guidance
-
Integra LifeSciences (IART) Tops Q2 EPS by 7c, Revenues Beat; Raises FY19 EPS Guidance, Affirms FY19 Revenue Outlook
-
Integra LifeSciences (IART) Tops Q1 EPS by 4c
-
Integra LifeSciences (IART) Tops Q4 EPS by 3c, Revenues Beat; Offers FY19 EPS Mid-Point Guidance Above Consensus, FY19 Revenue Views Below Estimates
-
Integra LifeSciences (IART) Reports In-Line Q3 EPS, Revenues Miss; Raises FY18 Revenue Outlook, Maintains FY18 EPS Guidance
-
Integra LifeSciences (IART) Reports In-Line Q2 EPS, Revenues Miss; Boosts FY18 EPS/Revenue Mid-Point Outlooks Below Consensus
-
Integra LifeSciences (IART) Tops Q1 EPS by 9c, Beats on Revenues; Boosts FY18 EPS/Revenue Outlook
-
Integra LifeSciences (IART) Tops Q4 EPS by 8c, Beats on Revenues; Offers FY18 EPS Guidance In-Line with Estimates
-
Integra LifeSciences (IART) Misses Q3 EPS by 2c; Lowers Outlook
-
Integra LifeSciences (IART) Reports In-Line Q2 EPS; Tightens FY Rev Range
-
Integra LifeSciences (IART) Misses Q1 EPS by 1c, Beats on Revenue, In-Line Fy Guidance
-
Integra LifeSciences (IART) Reports In-Line Q4 EPS, Offers FY Guidance
-
Integra LifeSciences (IART) to Buy J&J's (JNJ) Codman Neurosurgery Business for $1.05B
-
Integra LifeSciences (IART) to Acquire Derma Sciences (DSCI) for $7/Share, or 40% Premium
-
Integra LifeSciences (IART) Tops Q3 EPS by 4c
-
Integra LifeSciences (IART) Tops Q2 EPS by 3c; Boosts FY16 EPS Outlook
-
Integra LifeSciences (IART) Tops Q1 EPS by 1c
-
Integra LifeSciences (IART) Tops Q4 EPS by 1c, Offers FY Guidance
-
Integra LifeSciences (IART) Tops Q3 EPS by 1c, Updates FY Guidance
-
Integra LifeSciences (IART) Tops Q2 EPS by 3c; Updates FY15 Outlook
-
Integra LifeSciences (IART) Appoints New CEO
-
Integra LifeSciences (IART) Tops Q1 EPS by 13c
-
Integra LifeSciences (IART) Tops Q4 EPS by 5c
-
Integra LifeSciences (IART) Tops Q3 EPS by 2c; Will Spin Spine Business
-
Integra Lifesciences (IART) Tops Q2 EPS by 4c
-
Integra Lifesciences Holdings (IART) Misses Q1 EPS by 1c
-
Integra Lifesciences Holdings (IART) Misses Q4 EPS by 3c
-
Integra Lifesciences Holdings (IART) Tops Q3 EPS by 2c
-
Integra Lifesciences Holdings (IART) Tops Q2 EPS by 5c
-
Integra Lifesciences (IART) Misses Q1 EPS by 30c; Trims Outlook
-
Integra LifeSciences (IART) Issues Voluntary Recall of DuraGen Dural Graft Products
Back to IART Stock Lookup